New ALS drug tested for safety in small trial

NCT ID NCT04632225

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tested the safety of an experimental drug called engensis in 18 people with amyotrophic lateral sclerosis (ALS). Participants received either engensis or a placebo injection into their muscles. The main goal was to check for side effects, while also exploring effects on muscle strength, breathing, and quality of life. The study did not aim to cure ALS, but to see if the drug is safe enough for further testing.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Austin Neuromuscular Center

    Austin, Texas, 78759, United States

  • Hanyang University Medical Center

    Seoul, 04763, South Korea

  • Johns Hopkins University Department of Neurology

    Baltimore, Maryland, 21205, United States

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • St. Joseph's Hospital and Medical Center, Barrows Neurological Institute

    Phoenix, Arizona, 85013, United States